The differential signaling and outcome of patients with p190 or p210 transcripts of BCR-ABL1 have been systematically investigated in chronic myeloid leukemia rather than in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This evidence concerns the gene CNTNAP1 and chronic myelogenous leukemia, BCR-ABL1 positive.